Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifamycin Sodium

FDA-approved product (tablet, delayed release, oral), marketed as Aemcolo.

Registered studies
43
Lab records
6
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifamycin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Eye infection
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB03; WHO ATC A07AA13; WHO ATC D06AX15; WHO ATC S01AA16

Repurposing investigation

Rifamycin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli74.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae16.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 1 of 2 lab records
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 1 of 1 lab record
Open Rifamycin Sodium in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifamycin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

    NCT02393586 · start 2015-02

    Registered record
    Registry ID
    NCT02393586
    Conditions
    Tuberculosis
    Interventions
    Faropenem; Amoxicillin/clavulanic acid 500mg/125mg; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-10
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionFaropenem; Amoxicillin/clavulanic acid 500mg/125mg; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Immune Activation and Drug Absorption in HIV-Infected Patients

    NCT01845298 · start 2014-06

    Registered record
    Registry ID
    NCT01845298
    Conditions
    HIV Infection
    Interventions
    Rifampicin 600 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-06
    Completion
    2016-03-14
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionRifampicin 600 mg
    PhaseNot applicable
    Registry statusCompleted

  • Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial

    NCT01442428 · start 2014-01

    Registered record
    Registry ID
    NCT01442428
    Conditions
    Immune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids
    Interventions
    Dexamethasone; Atorvastatin; Naproxen; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2014-01
    Completion
    2016-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids
    InterventionDexamethasone; Atorvastatin; Naproxen; Placebo
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

    NCT01847664 · start 2013-08

    Registered record
    Registry ID
    NCT01847664
    Conditions
    Uncomplicated Diverticulitis
    Interventions
    Rifamycin SV-MMX® 400 mg b.i.d.; Rifamycin SV-MMX® 600 mg t.i.d.; Rifamycin SV-MMX® Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-07
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Diverticulitis
    InterventionRifamycin SV-MMX® 400 mg b.i.d.; Rifamycin SV-MMX® 600 mg t.i.d.; Rifamycin SV-MMX® Placebo
    PhasePhase 2
    Registry statusCompleted

  • Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

    NCT01208922 · start 2010-11

    Registered record
    Registry ID
    NCT01208922
    Conditions
    Traveler's Diarrhea
    Interventions
    Rifamycin SV-MMX®; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2016-05
    Enrolment
    835

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraveler's Diarrhea
    InterventionRifamycin SV-MMX®; Ciprofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra

    NCT01259219 · start 2010-11

    Registered record
    Registry ID
    NCT01259219
    Conditions
    Children With Confirmed HIV Infection; Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose; Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
    Interventions
    Mycobutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2010-11
    Completion
    2012-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren With Confirmed HIV Infection; Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose; Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
    InterventionMycobutin
    PhasePhase 1
    Registry statusUnknown

  • Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

    NCT01297855 · start 2010-06

    Registered record
    Registry ID
    NCT01297855
    Conditions
    Drug Safety
    Interventions
    Colistin; Colistin plus Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-06
    Completion
    2012-08
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Safety
    InterventionColistin; Colistin plus Rifampicin
    PhasePhase 3
    Registry statusUnknown

  • Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

    NCT01142089 · start 2010-05-27

    Registered record
    Registry ID
    NCT01142089
    Conditions
    Traveler's Diarrhea
    Interventions
    Placebo; Rifamycin SV MMX
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05-27
    Completion
    2012-06
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraveler's Diarrhea
    InterventionPlacebo; Rifamycin SV MMX
    PhasePhase 3
    Registry statusCompleted

  • Colistin and Rifampicin for MDR-Acinetobacter

    NCT01577862 · start 2008-11

    Registered record
    Registry ID
    NCT01577862
    Conditions
    Infection Due to Resistant Bacteria; Pneumonia, Ventilator-Associated; Hospital Acquired Pneumonia; Infection of Bloodstream; Infectious Disease of Abdomen
    Interventions
    Colistin; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-10
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Resistant Bacteria; Pneumonia, Ventilator-Associated; Hospital Acquired Pneumonia; Infection of Bloodstream +1 more
    InterventionColistin; Rifampicin
    PhasePhase 3
    Registry statusCompleted

  • Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

    NCT00621309 · start 2008-03

    Registered record
    Registry ID
    NCT00621309
    Conditions
    Adverse Drug Interactions
    Interventions
    Rifampicin; sulforaphane plus rifampicin; sulforaphane alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2010-09
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Interactions
    InterventionRifampicin; sulforaphane plus rifampicin; sulforaphane alone
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

    NCT03447821 · start 2008-02

    Registered record
    Registry ID
    NCT03447821
    Conditions
    Infectious Diarrhoea
    Interventions
    400 mg Rifamycin SV dosage; 800 mg Rifamycin SV dosage; 1200 mg Rifamycin SV dosage
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Diarrhoea
    Intervention400 mg Rifamycin SV dosage; 800 mg Rifamycin SV dosage; 1200 mg Rifamycin SV dosage
    PhasePhase 2
    Registry statusCompleted

  • Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects

    NCT00418756 · start 2006-10

    Registered record
    Registry ID
    NCT00418756
    Conditions
    Healthy
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-10
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNilotinib
    PhasePhase 1
    Registry statusCompleted

  • Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

    NCT00108862 · start 2006-08

    Registered record
    Registry ID
    NCT00108862
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Strategy: Immediate ART; Strategy: Deferred ART
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-08
    Completion
    2010-07
    Enrolment
    809

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStrategy: Immediate ART; Strategy: Deferred ART
    PhasePhase 4
    Registry statusCompleted